![]() |
市場調查報告書
商品編碼
2085707
胃腸內視鏡設備市場:2026-2032年全球市場預測(依產品類型、外形規格、類別、適應症、應用程式、最終用戶、年齡層和銷售管道)Gastrointestinal Endoscopy Devices Market by Product Type, Form Factor, Category, Indication, Application, End User, Age Group, Sales Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,胃腸內視鏡設備市場將成長至 185.5 億美元,複合年成長率為 5.43%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 128.1億美元 |
| 預計年份:2026年 | 134.8億美元 |
| 預測年份 2032 | 185.5億美元 |
| 複合年成長率 (%) | 5.43% |
胃腸內視鏡市場的發展主要受大腸直腸癌篩檢、消化道出血管理、發炎性腸道疾病後續觀察、膽道介入治療以及胃腸道疾病微創治療等重要診斷和治療需求的驅動。軟式內視鏡、內視鏡超音波系統、膠囊內視鏡、視覺化平台、供氣設備裝置、再處理系統、止血裝置、切片檢查鉗、勒除器、支架和能量系統配件等產品正構成一個日益整合的生態系統。
該領域正從傳統的診斷內視鏡轉向數位化連接、具備治療功能且工作流程最佳化的平台。隨著高解析度成像、窄頻和對比增強成像、一次性十二指腸內視鏡、先進的內視鏡超音波、膠囊內視鏡和內視鏡黏膜下剝離器械的出現,內視鏡的作用正從診斷擴展到包括器官保留手術。
人工智慧 (AI) 正在對整個胃腸內視鏡設備價值鏈產生累積影響。即時電腦輔助檢測結直腸息肉、評估取鏡時間和腸道準備品質、自動記錄、病變特徵分析以及提供培訓支援等功能,正推動人工智慧從試點部署走向領先醫療機構的常規臨床工作流程。
亞太地區是胃腸內視鏡設備市場最活躍的地區之一,中國、日本、印度、韓國、澳洲和東協市場都在加大對癌症篩檢、三級醫療服務和醫療技術在地化的投資。日本在內鏡技術創新、早期胃癌檢測和先進手術操作方面持續保持主導地位。同時,中國和印度正經歷著大規模的市場需求,這主要得益於其龐大的人口規模、人們對胃腸道疾病日益成長的認知、都市區醫院的擴建以及微創醫療的普及。韓國和澳洲則受惠於完善的篩檢基礎設施和日益普及的數位醫療,對高解析度影像、超音波和人工智慧平台的需求也日益成長。
在印尼、泰國、越南、馬來西亞、菲律賓和新加坡,由於專科醫療服務、私立醫院容量和癌症防治宣傳活動的擴展,東協地區的需求正在成長,但經濟負擔、保險報銷差異以及熟練內視鏡醫師的供應仍然存在不均衡的問題。海灣合作理事會(GCC)國家優先發展先進醫院、醫療旅遊、非傳染性疾病控制項目以及為重症患者提供專科醫療服務,這為高解析度成像系統、超音波、感染預防解決方案以及服務主導採購模式創造了機會。
在美國,胃腸內視鏡設備的普及應用正引領著以指南為基礎的結直腸癌篩檢、門診內視鏡中心的擴張、完善的保險報銷體係以及人工智慧影像和記錄工具的早期應用。加拿大致力於在各省醫療保健系統中實現篩檢的公平性和品質提升,而墨西哥和巴西則在公共部門大力推動癌症診斷和專科護理的同時,也見證了私營部門需求的成長。在歐洲,英國、德國、法國、義大利和西班牙受益於全國性的篩檢系統、先進的臨床中心以及對高解析度成像和治療性內視鏡技術的積極應用。俄羅斯對基礎內視鏡檢查的需求旺盛,但卻面臨採購、供應和地緣政治的限制。
產業領導者應該根據整個內視鏡工作流程來調整產品系列,而不是只專注於單一醫療設備。增值策略包括人工智慧成像平台、檢驗的感染預防解決方案、在臨床合理的情況下提供耐用和一次性產品選項,以及支援止血、內視鏡切除、引流、擴張和支架置入等治療程序的配件。
本執行摘要採用系統化的二手研究途徑編寫,重點關注檢驗的醫學、監管和臨床資訊來源。這些資訊來源包括世界衛生組織(WHO)、國際癌症研究機構(IARC)、美國預防服務工作小組(USPSTF)、美國食品藥物管理局(FDA)、歐盟委員會和各國癌症篩檢機構發布的公共指南。
胃腸內視鏡設備市場正進入一個技術密集階段,其促進因素是人們對大腸癌篩檢、微創治療、人工智慧視覺化、感染預防和品質的期望不斷提高。能夠將臨床效用與工作流程整合、合規性、互通性和培訓相結合的設備製造商,將更有能力滿足持續成長的手術需求。
The Gastrointestinal Endoscopy Devices Market is projected to grow by USD 18.55 billion at a CAGR of 5.43% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 12.81 billion |
| Estimated Year [2026] | USD 13.48 billion |
| Forecast Year [2032] | USD 18.55 billion |
| CAGR (%) | 5.43% |
The gastrointestinal endoscopy devices market is anchored by essential diagnostic and therapeutic demand across colorectal cancer screening, gastrointestinal bleeding management, inflammatory bowel disease surveillance, biliary intervention, and minimally invasive treatment of digestive disorders. Flexible endoscopes, endoscopic ultrasound systems, capsule endoscopy, visualization platforms, insufflators, reprocessing systems, hemostasis tools, biopsy forceps, snares, stents, and energy-based accessories form an increasingly integrated ecosystem.
Demand is supported by well-documented clinical need. The International Agency for Research on Cancer reported approximately 1.9 million new colorectal cancer cases worldwide in 2022, and the U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75. Evidence-based screening pathways continue to elevate procedure volumes, while hospitals and ambulatory endoscopy centers prioritize image quality, infection prevention, workflow efficiency, traceability, and AI-enabled lesion detection.
The landscape is shifting from conventional diagnostic endoscopy toward digitally connected, therapy-capable, and workflow-optimized platforms. High-definition imaging, narrow-band and contrast-enhanced visualization, single-use duodenoscopes, advanced endoscopic ultrasound, capsule endoscopy, and endoscopic submucosal dissection tools are expanding the role of endoscopy beyond diagnosis into organ-sparing intervention.
Operationally, providers are redesigning endoscopy suites around throughput, safety, and traceability. Heightened reprocessing scrutiny, device-related infection prevention guidance, and the need to reduce repeat procedures are influencing procurement. Vendors that combine clinical performance with service models, physician training, software upgrades, cybersecurity readiness, and regulatory compliance are better positioned as capital budgets become more selective.
Artificial intelligence is becoming a cumulative force across the gastrointestinal endoscopy devices value chain. Real-time computer-aided detection for colorectal polyps, quality metrics for withdrawal time and bowel preparation, automated documentation, lesion characterization, and training support are moving AI from pilot adoption to routine clinical workflow in leading centers.
The impact is not limited to diagnostic yield. AI can support capacity planning, procedure standardization, documentation consistency, and earlier escalation to therapeutic intervention when integrated with imaging systems and electronic health records. However, adoption depends on validated performance across diverse populations, transparent regulatory clearance, cybersecurity controls, interoperability, and clinician trust in outputs that augment rather than replace expert decision-making.
Asia-Pacific is one of the most dynamic regions for gastrointestinal endoscopy devices as China, Japan, India, South Korea, Australia, and ASEAN markets invest in cancer screening, tertiary care expansion, and medical technology localization. Japan remains a leader in endoscopic innovation, early gastric cancer detection, and advanced procedural expertise, while China and India present large-scale demand linked to population size, rising gastrointestinal disease awareness, urban hospital expansion, and broader access to minimally invasive care. South Korea and Australia add strong screening infrastructure and digital health adoption, supporting demand for premium visualization, endoscopic ultrasound, and AI-ready platforms.
North America benefits from established reimbursement, guideline-backed colorectal cancer screening, and a dense installed base of hospitals and ambulatory endoscopy centers. Europe is shaped by national screening programs, EU Medical Device Regulation requirements, clinical evidence expectations, and strong public procurement discipline. Latin America, led by Brazil and Mexico, is advancing through private hospital networks, public cancer control initiatives, and growing specialist capacity. The Middle East, particularly GCC countries, is investing in advanced hospitals, specialty care, and medical tourism infrastructure, while Africa remains underpenetrated but offers long-term opportunity as diagnostic capacity, referral pathways, and workforce training improve.
ASEAN demand is rising as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore expand specialist care, private hospital capacity, and cancer awareness programs, although affordability, reimbursement variability, and trained endoscopist availability remain uneven. GCC countries are prioritizing advanced hospitals, medical tourism, noncommunicable disease programs, and high-acuity specialty services, creating opportunities for premium visualization systems, endoscopic ultrasound, infection prevention solutions, and service-led procurement models.
The European Union is defined by harmonized regulatory oversight, value-based purchasing, national colorectal screening frameworks, and post-market surveillance expectations under strengthened medical device rules. BRICS markets combine large patient populations with domestic manufacturing ambitions, localization pressure, mixed reimbursement maturity, and expanding tertiary care access, requiring adaptable product portfolios and region-specific pricing models. G7 countries represent high-value innovation markets with strong clinical evidence expectations, advanced digital infrastructure, and rapid evaluation of AI-enabled endoscopy. NATO countries overlap significantly with mature Western health systems, where supply resilience, cybersecurity, procurement transparency, and critical medical technology availability increasingly shape device selection.
The United States leads adoption of gastrointestinal endoscopy devices through guideline-backed colorectal cancer screening, ambulatory endoscopy center growth, established reimbursement, and early uptake of AI-enabled imaging and documentation tools. Canada emphasizes equitable screening access and quality improvement across provincial health systems, while Mexico and Brazil show expanding private-sector demand alongside public initiatives for cancer diagnosis and specialty care. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from national screening frameworks, advanced clinical centers, and strong adoption of high-definition imaging and therapeutic endoscopy; Russia presents demand for essential endoscopy access but faces procurement, supply, and geopolitical constraints.
China is scaling domestic production, tertiary hospital capacity, and digestive disease diagnostics, supported by hospital modernization and rising awareness of colorectal and upper gastrointestinal cancers. India is expanding procedure access through urban hospital networks, specialist training, and private healthcare investment, though affordability and geographic access remain key constraints. Japan remains central to endoscopic technology development, early cancer detection practices, and advanced therapeutic procedures. Australia maintains strong screening infrastructure and quality-driven care pathways, while South Korea combines high screening participation, advanced hospitals, rapid digital health adoption, and strong procedural expertise, supporting demand for premium gastrointestinal endoscopy devices and software-enabled systems.
Industry leaders should align portfolios with the full endoscopy workflow rather than isolated devices. High-value strategies include AI-ready imaging platforms, validated infection prevention solutions, durable and single-use options where clinically justified, and accessories that support therapeutic procedures such as hemostasis, endoscopic resection, drainage, dilation, and stenting.
Commercial execution should focus on clinical evidence generation, physician training, total cost of ownership, interoperability, and region-specific reimbursement pathways. Manufacturers should strengthen supply chain redundancy, regulatory surveillance, cybersecurity compliance, product traceability, and post-market performance monitoring. Partnerships with hospitals, academic centers, ambulatory networks, and local distributors can accelerate adoption while supporting safe, standardized, and efficient gastrointestinal endoscopy procedure delivery.
This executive summary is developed using a structured secondary research approach focused on validated healthcare, regulatory, and clinical sources. Inputs include public guidance from organizations such as the World Health Organization, International Agency for Research on Cancer, U.S. Preventive Services Task Force, U.S. Food and Drug Administration, European Commission, and national cancer screening authorities.
The analysis synthesizes disease burden, screening recommendations, technology adoption, regulatory trends, care delivery models, procurement dynamics, and device safety considerations. Insights are cross-checked against peer-reviewed clinical literature, regulatory clearances, public health system publications, and recognized medical society guidance to ensure that conclusions remain evidence-based, market-relevant, and suitable for executive decision-making.
The gastrointestinal endoscopy devices market is entering a more technology-intensive phase shaped by colorectal cancer screening, minimally invasive therapy, AI-enabled visualization, infection prevention, and heightened quality expectations. Device makers that combine clinical utility with workflow integration, compliance, interoperability, and training will be best positioned to address sustained procedural demand.
Regional differences remain significant, but the direction of travel is consistent: earlier detection, safer procedures, better documentation, improved therapeutic capability, and expanded access to endoscopy services. Organizations that build credible clinical evidence, localize commercial models, strengthen supply resilience, and integrate AI responsibly can enhance competitiveness in both mature and emerging healthcare systems.